DK0586002T3 - Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho - Google Patents
Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indehoInfo
- Publication number
- DK0586002T3 DK0586002T3 DK93202428T DK93202428T DK0586002T3 DK 0586002 T3 DK0586002 T3 DK 0586002T3 DK 93202428 T DK93202428 T DK 93202428T DK 93202428 T DK93202428 T DK 93202428T DK 0586002 T3 DK0586002 T3 DK 0586002T3
- Authority
- DK
- Denmark
- Prior art keywords
- monoclonal antibody
- egf
- tumor cells
- inhibiting
- growth factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU1992100A CU22387A1 (es) | 1992-08-18 | 1992-08-18 | Anticuerpos monoclonados que reconocen el receptor del factor de crecimiento epidermico. procedimiento de obtencion |
CU1993017 | 1993-03-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0586002T3 true DK0586002T3 (da) | 2000-06-19 |
Family
ID=25746823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK93202428T DK0586002T3 (da) | 1992-08-18 | 1993-08-18 | Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0586002B1 (da) |
AT (1) | ATE188874T1 (da) |
DE (1) | DE69327620T2 (da) |
DK (1) | DK0586002T3 (da) |
ES (1) | ES2144440T3 (da) |
GR (1) | GR3033290T3 (da) |
PT (1) | PT586002E (da) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
DE69428764T2 (de) | 1993-12-24 | 2002-06-20 | Merck Patent Gmbh | Immunokonjugate |
CU22420A1 (es) * | 1993-12-29 | 1996-01-31 | Centro Inmunologia Molecular | Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer |
US6149921A (en) * | 1993-12-29 | 2000-11-21 | Centro De Inmunologia Molecular | Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment |
GB9405046D0 (en) * | 1994-03-15 | 1994-04-27 | Unilever Plc | Skin treatment composition |
CU22615A1 (es) * | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
DE69523857T2 (de) * | 1994-09-16 | 2002-06-13 | Merck Patent Gmbh | Immunokonjugate |
IT1277827B1 (it) * | 1995-03-01 | 1997-11-12 | Ministero Uni Ricerca Scient E | Anticorpo monoclonale chimerico murino/umano o un suo frammento specifico per il recettore egf (egf-r) |
ATE208403T1 (de) * | 1995-05-26 | 2001-11-15 | Merck Patent Gmbh | Antiidiotypische antikörper die eine immunantwort gegen den rezeptor für epidermalen wachstumsfaktor induzieren |
EP0745612B1 (en) * | 1995-05-26 | 2001-11-07 | MERCK PATENT GmbH | Anti-idiotypic antibodies which induce an immune response against epidermal growth factor receptor |
US5942602A (en) * | 1997-02-13 | 1999-08-24 | Schering Aktiengessellschaft | Growth factor receptor antibodies |
US20020173629A1 (en) | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
KR100480985B1 (ko) * | 2000-05-19 | 2005-04-07 | 이수화학 주식회사 | 표피 성장 인자 수용체에 대한 사람화된 항체 |
CU22979A1 (es) * | 2000-12-08 | 2004-09-09 | Centro Inmunologia Molecular | Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina |
EP2316951A1 (en) * | 2001-01-17 | 2011-05-04 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
CU23007A1 (es) * | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
EP1392359B2 (en) | 2001-05-11 | 2013-03-13 | Ludwig Institute for Cancer Research Ltd. | Specific binding proteins and uses thereof |
MXPA03011365A (es) | 2001-06-13 | 2005-03-07 | Genmab As | Anticuerpos monoclonales humanos para el receptor de factor de crecimiento epidermico (egfr). |
US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
DE10355904A1 (de) | 2003-11-29 | 2005-06-30 | Merck Patent Gmbh | Feste Formen von anti-EGFR-Antikörpern |
US10307481B2 (en) | 2005-07-25 | 2019-06-04 | Aptevo Research And Development Llc | CD37 immunotherapeutics and uses thereof |
NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
CN104013956B (zh) | 2007-01-25 | 2018-12-18 | 达娜-法勃肿瘤研究所公司 | 抗egfr抗体在治疗egfr突变体介导的疾病中的用途 |
WO2008115404A1 (en) | 2007-03-15 | 2008-09-25 | Ludwing Institute For Cancer Research | Treatment method using egfr antibodies and src inhibitors and related formulations |
ES2609915T3 (es) | 2007-08-14 | 2017-04-25 | Ludwig Institute For Cancer Research Ltd. | Anticuerpo monoclonal 175 direccionado al receptor de EGF y derivados y usos del mismo |
WO2009126944A1 (en) | 2008-04-11 | 2009-10-15 | Trubion Pharmaceuticals, Inc. | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
BRPI1006141B8 (pt) | 2009-01-12 | 2021-05-25 | Cytomx Therapeutics Llc | composições de anticorpo modificado, métodos para preparar e usar as mesmas |
CU24070B1 (es) * | 2011-12-27 | 2015-01-29 | Ct De Inmunología Molecular | Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3) |
DK3086814T3 (da) | 2013-12-23 | 2020-09-14 | Bayer Pharma AG | Binder-konjugater (adcs) med ksp-inhibitorer |
WO2016062851A1 (en) | 2014-10-23 | 2016-04-28 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
PE20180610A1 (es) | 2015-06-22 | 2018-04-09 | Bayer Pharma AG | CONJUGADOS DE LIGADOR-PRINCIPIO ACTIVO (ADCs) Y CONJUGADOS DE LIGADOR-PROFARMACO (APDCs) CON GRUPOS ENZIMATICAMENTE ESCINDIBLES |
BR112017027811A2 (pt) | 2015-06-23 | 2018-08-28 | Bayer Pharma AG | conjugados específicos de inibidores de ksp |
EP3328426B8 (en) | 2015-07-27 | 2021-06-02 | InnoCIMAb Pte Ltd | Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using monoclonal antibodies against the epidermal growth factor receptor (egfr) |
AU2016326449B2 (en) | 2015-09-21 | 2024-10-31 | Aptevo Research And Development Llc | CD3 binding polypeptides |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
JP7022707B2 (ja) | 2016-06-15 | 2022-02-18 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ksp阻害剤および抗cd123抗体を含む特異的抗体-薬物-コンジュゲート(adc) |
CA3047522A1 (en) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Specific antibody drug conjugates (adcs) having ksp inhibitors |
WO2018114578A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen |
AU2019414793A1 (en) | 2018-12-26 | 2021-06-24 | Innate Pharma | Compounds and methods for treatment of head and neck cancer |
-
1993
- 1993-08-18 EP EP93202428A patent/EP0586002B1/en not_active Expired - Lifetime
- 1993-08-18 DE DE69327620T patent/DE69327620T2/de not_active Expired - Lifetime
- 1993-08-18 ES ES93202428T patent/ES2144440T3/es not_active Expired - Lifetime
- 1993-08-18 AT AT93202428T patent/ATE188874T1/de active
- 1993-08-18 DK DK93202428T patent/DK0586002T3/da not_active Application Discontinuation
- 1993-08-18 PT PT93202428T patent/PT586002E/pt unknown
-
2000
- 2000-04-20 GR GR20000400972T patent/GR3033290T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP0586002A2 (en) | 1994-03-09 |
ES2144440T3 (es) | 2000-06-16 |
GR3033290T3 (en) | 2000-09-29 |
DE69327620T2 (de) | 2000-08-03 |
PT586002E (pt) | 2000-07-31 |
EP0586002B1 (en) | 2000-01-19 |
ATE188874T1 (de) | 2000-02-15 |
DE69327620D1 (de) | 2000-02-24 |
EP0586002A3 (en) | 1994-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0586002T3 (da) | Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho | |
NZ210867A (en) | Tumour-specific monoclonal antibodies, production thereof and use | |
PL311661A1 (en) | Single-chain anti-egfr fv and anti-egfr antibodies | |
AU2190997A (en) | Humanized anti-cd40 monoclonal antibodies and fragments capable of blocking b cell activation | |
WO1997019111A3 (es) | Anticuerpos monoclonales anti-cd6 y sus utilizaciones | |
HUP0101160A2 (hu) | Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására | |
IL135221A0 (en) | Natural humanized antibody and methods for the preparation thereof | |
AU2308595A (en) | Monoclonal antibodies against hiv-1 and vaccines made thereo f | |
WO2001005425A3 (en) | Combined preparations comprising daunorubicin derivatives and her2 antibodies | |
MD1374G2 (ro) | Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică | |
MX9705349A (es) | Anticuerpo monoclonal 1a7 y su uso para el tratamiento de melanona y carcinoma de celulas pequeñas. | |
MY137078A (en) | Recombinant antibodies associated to gangliosides. their use indiagnosis and treatment of tumors. | |
WO1996022373A3 (en) | Monoclonal antibody 1a7 and use for the treatment of melanoma and small cell carcinoma | |
EP0198086A4 (en) | MAN-MOUSE HYBRIDOMA PRODUCING HUMAN ANTIVIRAL ANTIBODY, PREPARATION METHOD AND HUMAN ANTIVIRAL MONOCLONAL ANTIBODY. | |
EP0194851A3 (en) | Human tumor therapy | |
EP0166458A3 (en) | Monoclonal antibody capable of specifically distinguishing human hepato-carcinoma cells | |
BG51405A1 (en) | Hybridome cellular line secreting monoclonal antibody ageinst human erythrocytec blood group antigen b | |
CS347090A3 (en) | Murine lymphocyte hybridoma tsh-51 producing monoclonal antibody of the class igg 2a against human thyrostimulative hormone | |
CS347190A3 (en) | Murine lymphocyte hybridoma tsh-116 producing monoclonal antibody of the class igg 2a against human thyrostimulative hormone | |
LTIP1867A (en) | Hybridoma producing murine monoclonal antibodies against human growth hormone | |
BG49665A1 (en) | Hybridom cell line, secreting monoclonal antibody against determinant 05 salmonelli of group b |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AHB | Application shelved due to non-payment |